Amyotrophic Lateral Sclerosis treated with Palmitoylethanolamide (Normast; PeaPure)
An interesting new therapeutic approach for the rehabilitation and Amyotrophic Lateral Sclerosis hasl been presented in Milan, during the second day of the XII National Congress of SIRN, the Italian Society of Neurological Rehabilitation.
The new hope in the treatment of ALS, neuro-degenerative disease that affects about one in every 100 (mostly men of middle or advanced age), and in 5% of cases are familial, comes from "palmitoylethanolamide" (PEA).
It is an endogenous compound with anti-inflammatory effect cannabinergico, discovered years ago by Italian scientists in the group that included, among others, the Nobel Prize Professor Rita Levi Montalcini.
PEA for ALS: further information
How to take PEA in the ALS?
Discovery is the author of Dr. Simonetta Clemente, the Rehabilitation Specialist who directs the Center for Rehabilitation of Macon ASL of Nuoro, assisted by a team of professionals where women reign supreme: Anna Carmela Pireddu, physiatrist, Giantonella Puggioni, internist, physiotherapists and Roberta Erdas, Sebastiano Rossi and Silvana Mastinu. The study will be presented in poster session, which is well suited to represent the results obtained through the numerous and significant photographic images. Since November of last year two patients with ALS (sporadic form in one case and another in the hereditary form), diagnosed with certainty at prestigious universities, have been subjected to administration of PEA.
"My goal – explains Dr. Clement – was to improve the effects of rehabilitation, that in ALS patients is rendered completely ineffective due to the degeneration of motor neurons and progressive muscle atrophy." "
The study – continues Clement – has shown that the PEA determines an immediate motor effect, blocking the progression of the disease, while the patient has a subjective perception of improvement and can do things which before were closed. This effect allows you to implement a rehabilitation plan that quickly determines the functional recovery, accompanied by the reappearance of the muscles. Of course, two cases are few. I hope that, after the Congress, it is possible to begin a multicenter research protocol with patients at different stages of severity, experiencing the active ingredient together with a targeted rehabilitation in order to drive the re-innervation, as in the two cases described ‘ .
The Director General of the Health of Nuoro, Dr. Antonio Maria Soru, expressed great satisfaction with the interesting therapeutic prospects identified:
"This is a first result that rewards the work of a respected professional company and the team that ‘has assisted in the study. But it is also an added incentive to encourage us all to support even more research and enhancing the many professionals working within the ASL of Nuoro, to contribute to improving care and quality of life for patients. "